Open report — full analysis, no account required.

Sign up to generate reports and read filings that aren't on the open list.

Sign up free

Get notified when PRAX files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NASDAQ: PRAX Praxis Precision Medicines, Inc. 8-K

Praxis rotates auditors from Ernst & Young to KPMG with clean separation

Filed July 2, 2026 · Period ending June 29, 2026 · ~1 min read

2 key changes 1 section

Key Changes

  • low

    Audit Committee dismissed Ernst & Young and engaged KPMG as independent auditor effective June 29, 2026, with no disagreements on accounting principles or reportable events during the transition period.

  • low

    Ernst & Young issued unqualified audit opinions on fiscal 2024 and 2025 financial statements with no modifications for uncertainty, scope, or accounting principles.

Summary

Praxis Precision Medicines rotated its independent auditor from Ernst & Young to KPMG effective June 29, 2026. The Audit Committee approved both the dismissal and the new engagement on the same date. The company explicitly disclosed no disagreements with Ernst & Young on accounting matters, financial statement disclosure, or audit procedures, and no reportable events occurred during the relevant period.

Ernst & Young's audit reports for fiscal years 2024 and 2025 were unqualified, with no adverse opinions or modifications. This is a routine auditor rotation with no adverse circumstances. The clean separation and unqualified prior opinions indicate normal governance processes. For retail holders, this filing has no material impact on the company's financial position or operations.

Section-by-Section Diff

Event · Item 4.01 — Changes in Registrant's Certifying Accountant

~500 words

Item 4.01 — Changes in Registrant's Certifying Accountant filed; see Key Changes for terms.

2 Added
Show 2 minor / wording changes
Added Auditor change: EY dismissed, KPMG engaged low

Added in current filing · verify on EDGAR →

On June 29, 2026, the Audit Committee of the Board of Directors (the "Audit Committee") of Praxis Precision Medicines, Inc. (the "Company") approved the dismissal of Ernst & Young LLP ("EY") as the Company's independent registered public accounting firm, effective as of that date.

The company dismissed Ernst & Young as its auditor and simultaneously engaged KPMG LLP on June 29, 2026. This is a routine auditor rotation with no adverse circumstances disclosed.

Added No disagreements or reportable events with EY low

Added in current filing · verify on EDGAR →

During the fiscal years ended December 31, 2025 and December 31, 2024 and through June 29, 2026, there were no: (i) disagreements (as defined in Item 304(a) (1) (iv) of Regulation S-K and the related instructions) with EY on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of EY, would have caused it to make reference to the subject matter of the disagreements in connection with its reports; or (ii) reportable events (as defined in Item 304(a) (1) (v) of Regulation S-K).

The company explicitly confirms there were no disagreements with EY on accounting principles, financial statement disclosure, or auditing procedures, and no reportable events occurred during the relevant period. This indicates a clean separation.

Was this report useful?

Figures/quotes linked to EDGAR · Narrative written by AI · Jul 3, 2026 · How we verify